Incyte's Strong Q4 Performance and Promising Growth Outlook Earns 'Buy' Rating
J.P. Morgan Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $70
JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating
UBS Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $69
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $88
Truist Financial Maintains Incyte(INCY.US) With Hold Rating
Jefferies Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $68
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $69 to $88
Analysts' Top Healthcare Picks: Incyte (INCY), Medpace Holdings (MEDP)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Alnylam Pharma (ALNY) and Nurix Therapeutics (NRIX)
UBS Cuts Price Target on Incyte to $69 From $77, Keeps Neutral Rating
Citigroup Maintains Buy on Incyte, Lowers Price Target to $88
Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating
TD Cowen Adjusts Price Target on Incyte to $88 From $86, Maintains Buy Rating
Incyte Receives Buy Rating Amid Strong Performance and Future Growth Potential
Incyte Price Target Raised to $77.00/Share From $75.00 by Stifel
Incyte Is Maintained at Hold by Stifel
Analysts' Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Incyte's Strong Financial Performance and Growth Prospects Justify Buy Rating
Unlock the Full List